DUGiDocsDNA damaging agents in ovarian cancer
dc.contributor.author
dc.date.accessioned
2021-05-12T06:54:22Z
dc.date.available
2021-05-12T06:54:22Z
dc.date.issued
2020-08
dc.identifier.uri
dc.description.abstract
Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging role of PARP inhibitors has changed the landscape of opportunities for patients with EOC. All these strategies will be reviewed in this article
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier
dc.relation.isformatof
Reproducció digital del document publicat a: https://doi.org/10.1016/j.ejcsup.2020.06.001
dc.relation.ispartof
European Journal of Cancer Supplements, 2020, vol. 15, p. 67-72
dc.relation.ispartofseries
Articles publicats (IdIBGi)
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri
dc.subject
dc.title
DNA damaging agents in ovarian cancer
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
dc.type.peerreviewed
peer-reviewed
dc.identifier.eissn
1359-6349